New COVID-19 vaccine candidate enters early human testing
NCT ID NCT05408312
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new recombinant COVID-19 vaccine (GEN2) in 234 healthy adults aged 18 and older. The main goal was to check safety and how well the body's immune system responds. Participants received one of three different doses or a placebo, and researchers monitored for side effects and antibody levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant SARS-CoV-2 Vaccine (CHO cells, NVSI-06-08)
What this could lead to
If successful, this could lead to a new COVID-19 vaccine option that is safe and triggers an immune response.
What could go wrong
This is an early Phase 1 trial with only 234 participants, so safety and effectiveness are not yet proven. The vaccine may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ning ling Center for Disease Control and Prevention
Shangqiu, Henan, China